Volume | 2,000 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Compass Therapeutics Inc | CMPX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.05 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 2,000 | - | 1.15 - 3.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
06:45:28 | formt | 2,000 | $ 2.00 | USD |
Compass Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
261.35M | 127.49M | - | 0 | -39.23M | -0.31 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Compass Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CMPX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.18 | 2.28 | 1.95 | 2.12 | 204,840 | -0.18 | -8.26% |
1 Month | 1.83 | 2.34 | 1.68 | 2.08 | 333,493 | 0.17 | 9.29% |
3 Months | 1.44 | 2.34 | 1.15 | 1.76 | 506,606 | 0.56 | 38.89% |
6 Months | 2.04 | 2.34 | 1.15 | 1.72 | 438,588 | -0.04 | -1.96% |
1 Year | 3.14 | 3.62 | 1.15 | 2.36 | 435,463 | -1.14 | -36.31% |
3 Years | 4.10 | 5.65 | 1.15 | 2.70 | 311,942 | -2.10 | -51.22% |
5 Years | 4.10 | 5.65 | 1.15 | 2.70 | 311,942 | -2.10 | -51.22% |
Compass Therapeutics Description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases. |